ReviewMayo Clinic proceedings2011
Bioidentical hormone therapy.
Review in Mayo Clinic proceedings, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Cardiovascular Changes in Menopause.Current cardiology reviews · 2021Pooled it
- Bioidentical hormones for women with vasomotor symptoms.The Cochrane database of systematic reviews · 2016Pooled it
- Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis.Systematic reviews · 2016Pooled it
- Distinct immunomodulatory effects of synthetic progestins compared with natural progesterone in human immune cells.ImmunoHorizons · 2026Article
- Psychedelics and women's mental health: the effects of female sex hormones on psychedelics' efficacy and tolerability.Molecular psychiatry · 2026Review
- The 2025 Menopausal Hormone Therapy Guidelines - Korean Society of Menopause.Journal of menopausal medicine · 2025Review
- Updates in Hormone Replacement Therapy for Survivors of Gynecologic Cancers.Current treatment options in oncology · 2025Review
- Glucocorticoids with or without fludrocortisone in septic shock: a narrative review from a biochemical and molecular perspective.British journal of anaesthesia · 2024Review
- Edible Bird's Nest Attenuates Menopause-Related Bone Degeneration in Rats via Increaing Bone Estrogen-Receptor Expression.Chinese journal of integrative medicine · 2021Article
- Clinically Used Hormone Formulations Differentially Impact Memory, Anxiety-Like, and Depressive-Like Behaviors in a Rat Model of Transitional Menopause.Frontiers in behavioral neuroscience · 2021Article
- Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors.Journal of women's health (2002) · 2019Article
- Abnormal Uterine Bleeding in AdolescentsJournal of clinical research in pediatric endocrinology · 2018Review
- Resveratrol supplementation rescues pool of growing follicles and ovarian stroma from Cisplatin-induced toxicity on the ovary in Sprague-Dawley rats: An experimental study.International journal of reproductive biomedicine · 2018Article
- Article
- Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making.BMC women's health · 2017Article
- Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells.Oncotarget · 2017Article
- State of the evidence 2017: an update on the connection between breast cancer and the environment.Environmental health : a global access science source · 2017Review
- The Association ofFrontiers in pharmacology · 2017Review
- Prescribing of FDA-approved and compounded hormone therapy differs by specialty.Menopause (New York, N.Y.) · 2016Article
- Benefits of Hormone Therapy Estrogens Depend on Estrogen Type: 17β-Estradiol and Conjugated Equine Estrogens Have Differential Effects on Cognitive, Anxiety-Like, and Depressive-Like Behaviors and Increase Tryptophan Hydroxylase-2 mRNA Levels in Dorsal Raphe Nucleus Subregions.Frontiers in neuroscience · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The change in hormonal milieu associated with perimenopause and menopause can lead to a variety of symptoms that can affect a woman's quality of life. Postmenopausal hormone therapy (HT) is an effective, well-tolerated treatment for these symptoms. However, combined HT consisting of conjugated equine estrogen and medroxyprogesterone acetate has been associated with an increased number of health risks when compared with conjugated equine estrogen alone or placebo. As a result, some women are turning to alternative hormonal formulations known as compounded bioidentical HT because they perceive them to be a safer alternative. This article defines compounded bioidentical HT and explores the similarities and differences between it and US Food and Drug Administration-approved HT. We will examine the major claims made by proponents of compounded bioidentical HT and recommend strategies for management of patients who request bioidentical HT from physicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.